WallStreetZenWallStreetZen

NASDAQ: RLYB
Rallybio Corp Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RLYB

Based on 1 analyst offering 12 month price targets for Rallybio Corp

Min Forecast
$5.00+1,443.21%
Avg Forecast
$5.00+1,443.21%
Max Forecast
$5.00+1,443.21%

Should I buy or sell RLYB stock?

Based on 1 analyst offering ratings for Rallybio Corp.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RLYB stock forecasts and price targets.

RLYB stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-17

1 of 1

Forecast return on equity

Is RLYB forecast to generate an efficient return?

Company
N/A
Industry
140.91%
Market
90.47%

Forecast return on assets

Is RLYB forecast to generate an efficient return on assets?

Company
N/A
Industry
32.45%

RLYB earnings per share forecast

What is RLYB's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$0.83
Avg 2 year Forecast
-$0.85

RLYB revenue growth forecast

How is RLYB forecast to perform vs Biotechnology companies and vs the US market?

Company
513.83%
Industry
56.38%
Market
9.68%
RLYB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
RLYB's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

RLYB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RLYB$0.32$5.00+1,443.21%Buy
EDSA$1.92$21.00+993.75%Buy
UBX$0.80$3.00+275.94%Buy
ABP$0.22$4.00+1,760.47%Strong Buy
NEUP$6.82$21.00+208.10%Buy
View Top Biotech Stocks

Rallybio Stock Forecast FAQ

Is Rallybio Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: RLYB) stock is to Buy RLYB stock.

Out of 1 analyst, 0 (0%) are recommending RLYB as a Strong Buy, 1 (100%) are recommending RLYB as a Buy, 0 (0%) are recommending RLYB as a Hold, 0 (0%) are recommending RLYB as a Sell, and 0 (0%) are recommending RLYB as a Strong Sell.

If you're new to stock investing, here's how to buy Rallybio stock.

What is RLYB's earnings growth forecast for 2025-2026?

(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Rallybio's earnings in 2025 is -$48,185,000.On average, 1 Wall Street analyst forecast RLYB's earnings for 2025 to be -$34,539,590, with the lowest RLYB earnings forecast at -$34,539,590, and the highest RLYB earnings forecast at -$34,539,590.

In 2026, RLYB is forecast to generate -$35,371,869 in earnings, with the lowest earnings forecast at -$35,371,869 and the highest earnings forecast at -$35,371,869.

What is RLYB's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: RLYB) forecast ROE is N/A, which is considered weak.

What is RLYB's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RLYB price target, the average RLYB price target is $5.00, with the highest RLYB stock price forecast at $5.00 and the lowest RLYB stock price forecast at $5.00.

The Wall Street analyst predicted that Rallybio's share price could reach $5.00 by Mar 17, 2026. The average Rallybio stock price prediction forecasts a potential upside of 1,443.21% from the current RLYB share price of $0.32.

What is RLYB's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: RLYB) Rallybio's current Earnings Per Share (EPS) is -$1.09. On average, analysts forecast that RLYB's EPS will be -$0.83 for 2025, with the lowest EPS forecast at -$0.83, and the highest EPS forecast at -$0.83. In 2026, RLYB's EPS is forecast to hit -$0.85 (min: -$0.85, max: -$0.85).

What is RLYB's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: RLYB) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 32.45%.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.